PA8846101A1 - Anticuerpos del receptor ii anti-tgf-beta - Google Patents

Anticuerpos del receptor ii anti-tgf-beta

Info

Publication number
PA8846101A1
PA8846101A1 PA20098846101A PA8846101A PA8846101A1 PA 8846101 A1 PA8846101 A1 PA 8846101A1 PA 20098846101 A PA20098846101 A PA 20098846101A PA 8846101 A PA8846101 A PA 8846101A PA 8846101 A1 PA8846101 A1 PA 8846101A1
Authority
PA
Panama
Prior art keywords
antibodies
tgf
receiver
beta
beta receiver
Prior art date
Application number
PA20098846101A
Other languages
English (en)
Spanish (es)
Inventor
Wu Yan
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PA8846101A1 publication Critical patent/PA8846101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PA20098846101A 2008-11-07 2009-10-19 Anticuerpos del receptor ii anti-tgf-beta PA8846101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19869708P 2008-11-07 2008-11-07
US17036909P 2009-04-17 2009-04-17

Publications (1)

Publication Number Publication Date
PA8846101A1 true PA8846101A1 (es) 2010-06-28

Family

ID=41508691

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098846101A PA8846101A1 (es) 2008-11-07 2009-10-19 Anticuerpos del receptor ii anti-tgf-beta

Country Status (19)

Country Link
US (2) US8147834B2 (https=)
EP (1) EP2356152A1 (https=)
JP (1) JP5667067B2 (https=)
KR (1) KR101283856B1 (https=)
CN (1) CN102209727B (https=)
AR (1) AR073909A1 (https=)
AU (1) AU2009311375B2 (https=)
BR (1) BRPI0921263A2 (https=)
CA (1) CA2742961C (https=)
EA (1) EA025169B1 (https=)
IL (1) IL211842A (https=)
JO (1) JO3096B1 (https=)
MX (1) MX2011004871A (https=)
NZ (1) NZ591943A (https=)
PA (1) PA8846101A1 (https=)
SG (1) SG10201401280TA (https=)
TW (1) TWI384998B (https=)
WO (1) WO2010053814A1 (https=)
ZA (1) ZA201103178B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093125A1 (en) * 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
US10828353B2 (en) 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
MX2018014256A (es) * 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
AR109770A1 (es) 2016-10-18 2019-01-23 Lilly Co Eli ANTICUERPOS DEL RECEPTOR II DE TGF-b
BR112019013908A2 (pt) * 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos
CN106884005A (zh) * 2017-01-19 2017-06-23 樊克兴 一种结直肠癌抗原特异性t细胞的制备方法
WO2019084057A2 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
KR20200069364A (ko) 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN107973853B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2023020625A1 (zh) * 2021-08-20 2023-02-23 中山康方生物医药有限公司 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途
WO2023198194A1 (en) * 2022-04-15 2023-10-19 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-cd40 antibodies and uses thereof
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) * 2002-08-07 2004-04-22 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT

Also Published As

Publication number Publication date
WO2010053814A1 (en) 2010-05-14
ZA201103178B (en) 2012-10-31
MX2011004871A (es) 2011-07-13
CN102209727B (zh) 2014-07-30
US20100119516A1 (en) 2010-05-13
CA2742961A1 (en) 2010-05-14
TWI384998B (zh) 2013-02-11
TW201026326A (en) 2010-07-16
BRPI0921263A2 (pt) 2015-08-04
US8147834B2 (en) 2012-04-03
US20120177666A1 (en) 2012-07-12
CA2742961C (en) 2016-08-30
KR20110067155A (ko) 2011-06-21
JP5667067B2 (ja) 2015-02-12
IL211842A0 (en) 2011-06-30
SG10201401280TA (en) 2014-05-29
AU2009311375B2 (en) 2014-07-31
CN102209727A (zh) 2011-10-05
IL211842A (en) 2016-09-29
EA025169B1 (ru) 2016-11-30
AU2009311375A1 (en) 2010-05-14
EA201170659A1 (ru) 2011-10-31
NZ591943A (en) 2012-11-30
JO3096B1 (ar) 2017-03-15
EP2356152A1 (en) 2011-08-17
AR073909A1 (es) 2010-12-09
KR101283856B1 (ko) 2013-07-15
JP2012508170A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
SV2011004043A (es) Composiciones y metodos para aumentar el crecimiento muscular
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
GT201400283A (es) Formas cristalinas de un modulador del receptor androgénico
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
GT201400111A (es) Triazolopiridinas sustituidas
ECSP10010295A (es) Formulacion de anticuerpo
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
MX2012003413A (es) Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
CO6280406A2 (es) Polipeptidos anti-microbianos para uso en el tratamiento de transtornos microbianos
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
UY31622A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CR20120264A (es) Compuestos
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
MX2012007164A (es) Composiciones para el cuidado oral.